To further explore the role of ICI scores in predicting the therapeutic benefit in GC, the patients who accepted anti-PD-L1 immunotherapy from the IMvigor210 cohort were calculated ICI scores and assigned into high- or low-ICI scores groups (Supplementary Table S8). Here, CD274 is linked to gastric cancer.